MAT1A and metabolic dysfunction-associated steatotic liver disease: Although the different subtypes were equally represented in the NAFLD and NASH patients analyzed, which suggests that subtypes did not distinguish higher risk to develop NASH, the authors explained that s-adenosylmethionine therapy could be a better therapeutic approach for those patients with a subtype more similar to that of MAT1A-KO mice [33].